Joanna M. Rhodes, MD, MSCE

Panelists discuss how they balance the potential benefits of aggressive first-line treatment in chronic lymphocytic leukemia against the importance of preserving effective options for subsequent lines of therapy, considering factors such as patient prognosis, treatment goals, and the evolving landscape of available therapies.

Panelists discuss how they approach treatment sequencing in relapsed/refractory chronic lymphocytic leukemia (CLL), considering primary factors such as prior therapies, mechanisms of resistance, patient characteristics, and treatment goals to optimize the order and selection of subsequent therapies for improved long-term outcomes.

Panelists discuss how they approach treatment selection for multi-refractory chronic lymphocytic leukemia (CLL) patients, considering factors such as prior therapy responses, patient fitness, and disease characteristics to guide choices among available options, including CAR T-cell therapy, while also addressing the limitations and challenges associated with each treatment modality in their decision-making process.

Panelists discuss how various additional treatment options for relapsed/refractory chronic lymphocytic leukemia (CLL) are considered, including CAR-T cell therapy, immunomodulatory drugs like lenalidomide, chemoimmunotherapy regimens, and other emerging therapies, highlighting their potential roles in the evolving treatment landscape.

Panelists discuss how they evaluate patients for tumor lysis syndrome (TLS) risk, considering factors such as tumor burden, renal function, and prior therapies, and how this assessment influences their decision between prescribing a non-covalent BTK inhibitor or a venetoclax-based regimen for chronic lymphocytic leukemia treatment.

Panelists discuss how utilizing pirtobrutinib in clinical practice, focusing on its application in patients who have developed resistance or intolerance to prior BTK inhibitors, as well as in those who have shown resistance to both BTK and BCL-2 inhibitors in chronic lymphocytic leukemia treatment.

Panelists discuss how the non-covalent BTK inhibitor pirtobrutinib has shown promising results in the BRUIN clinical trials for both BTK inhibitor-naive and previously treated chronic lymphocytic leukemia patients, reviewing key efficacy and safety data presented at recent hematology conferences.

Panelists discuss how they assess patients for resistance to first-line BTK inhibitor therapy in chronic lymphocytic leukemia, emphasizing the importance of clinical evaluation, laboratory testing, and genetic analysis in determining the presence and mechanisms of resistance to guide subsequent treatment decisions.

Panelists discuss how treatment approaches are tailored differently for patients with rapid, aggressive chronic lymphocytic leukemia progression versus those with slower, less aggressive disease, considering factors such as urgency of intervention, choice of therapy intensity, and long-term management strategies.

Panelists discuss how various patient-specific factors, including age, comorbidities, performance status, disease aggressiveness, symptoms, and biomarkers, are carefully considered to guide the selection of optimal treatment strategies for individuals with chronic lymphocytic leukemia (CLL).

Panelists discuss how the choice of prior therapy between BTK inhibitors and BCL2 inhibitors influences subsequent treatment decisions in chronic lymphocytic leukemia (CLL), considering factors such as resistance mechanisms, toxicity profiles, and patient-specific characteristics.

Panelists discuss the current standard of care and treatment landscape for patients with chronic lymphocytic leukemia.

A panel of expert oncologists offer closing thoughts on the future treatment landscape and unmet needs in CLL.

Expert oncologists explore emerging therapies being investigated in CLL, including BTKi degraders, CAR-T therapy, and bispecific antibodies, and discussed their potential impact in shaping the future of CLL treatment.

The expert panel discusses recent data regarding the mechanisms of resistance to non-covalent BTK inhibitors in CLL.

Jacqueline Barrientos, MD, MS, discusses the role of non-covalent BTK inhibitors in R/R CLL and provided concise comments on the latest data, including insights from the ongoing BRUIN and Bellwave trials.

Javier Pinilla, MD, PhD explores evidence on molecular mechanisms leading to resistance in second-generation BTK inhibitors for CLL, providing insights from recently presented data at ASH 2023.

A panel of expert oncologists explore the influence of hypertension risk and other cardiovascular AEs in guiding treatment selection with BTKis, sharing insights from ASH 2023.

Faculty provide insights into the selection of BTK inhibitors, emphasizing the role of efficacy, toxicity, and quality of life data in treatment decisions, and exploring the impact of MAIC data.

Panel experts examine considerations for BTKi-based strategies in R/R CLL, highlighting pivotal findings from head-to-head trials, including acalabrutinib vs ibrutinib in ELEVATE-RR and zanubrutinib vs ibrutinib in ALPINE, covering safety, quality of life, and extended follow-up data.

Faculty share insights into the overall strategy for managing relapsed/refractory CLL following first-line therapy with venetoclax-based regimens and BTK inhibitors, discussing strategy variations based on prior first-line treatments.

Experts explore the role of BTKi-based combination therapy in the front-line treatment of CLL, focusing on patient considerations and referencing key data from CAPTIVATE, FLAIR, MAJIC, and SEQUOIA (Arm D).

Javier Pinilla, MD, PhD, provides a brief overview of the changing CLL treatment landscape, discussing the influence of off-target adverse events and the development of treatment resistance on the evolution of BTK inhibitor therapy.

Joanna Rhodes, MD, MSCE, explores the general approach to treatment-naïve CLL patients with high-risk factors such as del17p and TP53 mutations.

Brian Hill, MD, PhD, discusses the use of BTK inhibitor monotherapy in CLL and presented recent long-term data updates from studies such as the 6-year follow-up of ELEVATE-TN and the extended follow-up from SEQUOIA.

Joanna M. Rhodes, MD, MSCE, discusses the use of pirtobrutinib after covalent BTK inhibition in chronic lymphocytic leukemia or small lymphocytic lymphoma.

Catherine Coombs, MD discusses the present CLL front-line treatment landscape, addressing considerations like choosing fixed-duration or continuous therapy and variations in first-line approaches based on age and ECOG status.

Closing out their discussion on the management of relapsed/refractory diffuse large B-cell lymphoma, expert panelists highlight unmet needs and share excitement for future evolutions in the treatment landscape.

Key opinion leaders reflect on data from the 2023 ASCO meeting and how it may impact the management of diffuse large B-cell lymphoma.

Expert perspectives on recent efforts to move novel therapy from the relapsed/refractory to frontline setting of diffuse large B-cell lymphoma.